Akebia plunges 20% on muted Q1 print
Akebia's stock fell by 20% following its first-quarter earnings report. The pharmaceutical company's Q1 results were described as muted, leading to a significant drop in its share price.
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia
State Street Corporation has disclosed a passive ownership of 11,614,006 shares, representing a 4.3% stake, in Akebia Therapeutics Inc. as of March 31, 2026. This filing, a Schedule 13G, indicates that the shares are held for investment purposes rather than control, with shared voting power for 11,269,922 shares and shared dispositive power for all 11,614,006 shares. The report was signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer of State Street Corporation, on May 12, 2026.
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
Akebia Therapeutics, Inc. experienced a 23% stock drop after its first-quarter report, despite revenues beating expectations. Analysts have mixed opinions, downgrading revenue forecasts for 2026 and increasing per-share loss estimates, while the average price target remained unchanged at US$4.20. The company's revenue is expected to decline significantly, contrasting with the broader industry's forecast for growth.
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
Akebia Therapeutics (NASDAQ:AKBA) experienced a significant share price drop of 23% following its first-quarter results, despite revenues exceeding expectations. Analysts have mixed opinions, downgrading revenue forecasts to $216.2m for 2026 and increasing expected per-share losses to $0.13, while the average price target remained broadly unchanged at US$4.20, suggesting that the weaker earnings outlook may not impact long-term valuation. The company's projected revenue decline is steeper than the broader industry's expected growth.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts
Akebia Therapeutics (NASDAQ:AKBA) has an average analyst rating of "Hold" based on five brokerage coverages, with a split between two sell and three buy ratings, and an average 12-month price target of $4.67. Recent analyst actions included both upgrades and downgrades, while the company reported revenue exceeding estimates but missed EPS expectations. Shares opened near their 52-week low, and insider buying was also noted.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) reported a Q1 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.01 loss, and also fell short on revenue expectations with $53.54 million against an anticipated $5.2 million. The company's stock has declined 8.1% year-to-date, prompting a Zacks Rank #5 (Strong Sell) due to unfavorable earnings estimate revisions. Investors are advised to monitor management's commentary and industry outlook for future performance.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. reported its Q1 2026 earnings, with strong growth in Vafseo net product revenues, reaching $15.8 million, a 32% increase year-over-year, despite missing EPS expectations. The company highlighted increased prescriber engagement and patient adoption of Vafseo, driven by observed dosing protocols across dialysis organizations. Akebia also provided updates on its pipeline, including ongoing Phase II trials for praliciguat in FSGS and a planned Phase II trial for AKB-097, a novel complement inhibitor.
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright
H.C. Wainwright reiterated a Buy rating for Akebia Therapeutics (AKBA) with a $6.00 price target, following a positive assessment from analyst Matthew Caufield. The company reported a Q4 revenue of $57.62 million and a GAAP net loss of $12.24 million, showing improved financial performance year-over-year. Insider sentiment is positive, with an increase in insider buying, including CEO John P. Butler's purchase of 69,270 shares in March 2026.
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan
Akebia Therapeutics (AKBA) stock dropped 14.5% after the company reported a swing to a Q1 net loss of US$9.05 million from a net income of US$6.11 million a year prior, on reduced revenue. The company also proposed increasing its authorized capital stock, including common shares, which raises concerns about potential dilution for investors. These financial results and the potential for dilution underscore the challenges Akebia faces in achieving sustainable profitability and funding future commercialization efforts.
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Akebia Therapeutics (NASDAQ:AKBA) from "hold" to "sell," aligning with a mixed analyst sentiment that gives the stock a consensus "Hold" rating and an average target price of $4.67. The biopharmaceutical company recently reported missed EPS estimates but beat revenue expectations, while facing ongoing profitability challenges and trading near its 52-week low. Despite the downgrade, CEO John P. Butler and several institutional investors have increased their stakes in the company.
Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report
This entry is a placeholder for Akebia Therapeutics' Q1 2026 Earnings Report (Form 10-Q). The actual detailed content of the report is not provided in this snippet but is indicated to be a formal document.
AKBA SEC Filings - Akebia Therapeut 10-K, 10-Q, 8-K Forms
This page provides access to Akebia Therapeutics (AKBA) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It aggregates regulatory disclosures related to the biopharmaceutical company's kidney disease focus, products like Vafseo and Auryxia, and clinical developments. The platform also offers AI-powered summaries for quicker understanding of these financial documents.
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript
This is a transcript of Akebia Therapeutics Inc.'s Q1 2026 earnings call, held on May 7, 2026. The call covered the company's financial results for the first quarter of 2026, with an opening statement from an unidentified speaker and a presentation from Mercedes Carrasco. Following the presentation, a question-and-answer session was scheduled for participants.
Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS
Akebia Therapeutics (NASDAQ:AKBA) reported Q1 adjusted earnings per share of ($0.03), missing analysts' estimates by $0.02, despite revenue of $53.5 million exceeding expectations. The company sustained a net loss of $9.1 million due to higher costs but noted strong commercial traction for its product Vafseo and progress in its clinical pipeline. Akebia maintains a cash balance of $162.6 million, providing a runway for at least two years.
Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives
Akebia Therapeutics (AKBA) reported Q1 2026 revenue of US$53.5 million and a net loss of US$9.1 million, a significant reduction from previous losses. While revenue growth trails the broader market, the narrowing losses are seen as a positive by bulls, suggesting a potential path to profitability within three years. However, bears remain cautious due to slower revenue growth, reliance on key products, and historical volatility in earnings.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics reported its first quarter 2026 financial results, highlighting a significant increase in Vafseo net product revenues to $15.8 million and a 60% increase in patients treated with Vafseo compared to Q4 2025. The company also provided updates on its kidney disease pipeline, including progress in the praliciguat Phase 2 clinical trial for FSGS and plans for new studies for AKB-097 and AKB-9090. Despite a net loss of $9.1 million for the quarter, Akebia expects its current cash resources to fund operations for at least two years.
Akebia says more dialysis patients are using Vafseo as sales hit $15.8M
Akebia Therapeutics reported Q1 2026 results with Vafseo net product revenues reaching $15.8 million, driven by a 60% increase in patients and 28% increase in prescribers compared to Q4 2025. Despite this growth, the company posted a net loss of $9.1 million due to lower total revenues and higher expenses, including inventory write-downs and increased R&D costs. Akebia reiterated pipeline progress with praliciguat Phase 2 enrollment and planned studies for AKB-097 and AKB-9090, while also expecting its cash reserves to fund operations for at least two years.
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Akebia Therapeutics, Inc. (AKBA) reported its earnings for the first quarter ended March 31, 2026. The company experienced a decrease in revenue to USD 53.54 million from USD 57.34 million in the prior year and reported a net loss of USD 9.05 million, compared to a net income of USD 6.11 million a year ago. This resulted in a basic and diluted loss per share of USD 0.03 for continuing operations, a shift from basic and diluted earnings per share of USD 0.03 in the same period last year.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) reported a Q1 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.01 loss and falling short of year-ago earnings. The company also posted Q1 revenues of $53.54 million, which missed the consensus estimate by 5.2%. Due to an unfavorable earnings estimate revisions trend, Akebia Therapeutics currently holds a Zacks Rank #5 (Strong Sell).
Akebia Therapeutics Releases Q1 2026 Financial Results
Akebia Therapeutics (AKBA) reported Q1 2026 financial results, with a diluted loss per share matching analyst expectations at -$0.03. The company posted a net loss of $9.1M, a significant decrease from profitability in Q1 2025, and generated $53.5M in revenue, down 6.6% year-over-year. While Auryxia revenue declined, the company continues to navigate a challenging commercial environment, with analysts maintaining a generally positive outlook.
Akebia plunges 20% on muted Q1 print
Akebia Therapeutics (AKBA) stock plunged over 20% following its Q1 earnings report. The pharmaceutical company reported a Q1 loss of -$0.03 per share, meeting analyst expectations, while its revenue of $53.5 million surpassed consensus estimates. Despite beating on revenue, the "muted print" led to a significant drop in its stock price.
Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth
Akebia Therapeutics reported a net loss of $9.1 million in Q1 2026, a reversal from net income in the prior year, primarily due to a decline in Auryxia sales which was partly offset by growth in Vafseo revenue. Vafseo showed strong performance with significant increases in patients and prescribers, while Auryxia faced increasing generic competition. The company is actively investing in its kidney disease pipeline and expects its current cash reserves to fund operations for at least two years.
Akebia Therapeutics: Q1 Earnings Snapshot
Akebia Therapeutics (AKBA) reported a first-quarter loss of $9.1 million, or 3 cents per share, missing Wall Street expectations. The company's revenue of $53.5 million also fell short of analyst forecasts. Akebia's shares closed at $1.49, down from $2.32 a year prior.
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday
Akebia Therapeutics (AKBA) is scheduled to announce its Q1 2026 earnings before market open on May 7th, with analysts forecasting a loss of ($0.01) per share and revenues of approximately $51.67 million. The company missed EPS estimates in the previous quarter but exceeded revenue expectations. Despite current unprofitability, Insider John P. Butler purchased shares, and Wall Street maintains a "Hold" consensus rating with a $4.67 average price target.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics reported its Q1 2026 financial results, showing Vafseo net product revenues reaching $15.8 million with a 60% increase in patients treated compared to Q4 2025. The company also highlighted progress in its kidney disease pipeline, including patient enrollment in a Phase 2 clinical trial for praliciguat in FSGS and plans for a Phase 2 open-label basket study for AKB-097. Despite a net loss of $9.1 million for the quarter, Akebia expects its cash resources to fund operations for at least two years.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced the grant of stock options to seven newly-hired employees, totaling 208,800 shares of common stock. These inducement grants, made on April 30, 2026, are part of the company's employment agreements and comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.38 per share and vest over four years, contingent on continued employment.
Akebia gives 7 new hires stock options tied to 208,800 shares
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options for 208,800 shares to seven new employees on April 30, 2026. The options have an exercise price of $1.38 per share, a four-year vesting schedule, and a 10-year term, issued under Nasdaq Listing Rule 5635(c)(4). This move is part of the company's routine corporate actions, alongside its recent clinical and governance updates, with shares currently trading below their 200-day moving average.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. has granted stock options to seven newly-hired employees, totaling 208,800 shares of common stock. These inducement grants, made on April 30, 2026, are in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.38 per share, vesting over four years.
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Akebia Therapeutics announced that a post-hoc analysis of its Phase 3 INNO2VATE program for vadadustat, published in the Journal of the American Society of Nephrology (JASN), demonstrated a statistically significant reduction in all-cause mortality and hospitalization. This analysis reinforces the clinical differentiation of Vafseo® (vadadustat) for treating anemia due to chronic kidney disease in dialysis-dependent patients. The company believes this validation in a prominent peer-reviewed journal will support engagement with prescribers, providers, and payors, as they aim to make Vafseo a standard of care.
Akebia Therapeutics Announces Vadadustat Post-hoc Win
Akebia Therapeutics announced the publication of a post-hoc win statistics analysis of its Phase 3 INNO2VATE program for vadadustat (Vafseo) in the Journal of the American Society of Nephrology. This analysis demonstrated a statistically significant improvement relative to darbepoetin alfa in reducing all-cause mortality and hospitalization in dialysis-dependent CKD patients with anemia. Akebia believes these findings enhance Vafseo's clinical differentiation and support its goal of making it a standard of care.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its first-quarter 2026 financial results on May 8, 2026, before the market opens. The company will also host a conference call and webcast to discuss these results and provide business updates. This event is an opportunity for investors and stakeholders to get insights into Akebia's recent performance and future outlook.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before financial markets open. The company will host a conference call on the same day at 8:00 a.m. EDT to discuss these results and recent business highlights. Interested parties can register via a provided link or access a live webcast on Akebia’s investor relations website.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its first-quarter 2026 financial results on May 7, 2026, before market open. The company will host a conference call on the same day at 8:00 a.m. EDT to discuss these results and recent business highlights. Akebia Therapeutics is a biopharmaceutical company focused on kidney disease.
Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving Average - Time to Sell?
Akebia Therapeutics (NASDAQ:AKBA) saw its share price drop below its 200-day moving average to $1.38, indicating potential bearish sentiment. Despite this, the company reported positive quarterly earnings, beating revenue estimates. Analysts currently have an average "Hold" rating on the stock with a consensus price target of $4.67, significantly higher than its current trading price. The article highlights recent insider trading activities and institutional investment changes.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its first-quarter 2026 financial results on Thursday, May 7, 2026, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss these results and recent business highlights. Interested parties can register for the call via a provided link or access a live webcast on Akebia's investor website.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics will release its first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The company will host a conference call on the same day at 8:00 a.m. EDT to discuss these results and recent business developments. Interested parties can register for the call via a provided link or access a live webcast on Akebia's investor relations website.
Are options traders betting on a big move in Akebia Therapeutics stock?
This article provides no content on Akebia Therapeutics, other than its title. More information is needed to create a summary.
[ARS] Akebia Therapeutics, Inc. SEC Filing
This article reports on an SEC ARS filing by Akebia Therapeutics, Inc. (AKBA) on April 28, 2026. It provides details on the filing's low impact and neutral sentiment, along with links to the full PDF document and related company information. The article also lists recent news and other SEC filings for Akebia Therapeutics.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will report its Q1 2026 financial results on Thursday, May 7, 2026, before market open. The company will host a conference call on the same day at 8:00 a.m. EDT to discuss these results and recent business highlights. Investors can register for the call or access a live webcast and archive via Akebia’s investor relations website.
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares
Akebia Therapeutics is seeking shareholder approval to significantly increase its authorized common shares from 350 million to 500 million, and total capital stock from 375 million to 525 million, at its virtual 2026 annual meeting on June 17, 2026. This move aims to provide the company with greater flexibility for future financing, strategic deals, and equity incentives without requiring further charter amendments. Shareholders will also vote on director elections, executive compensation, its frequency, and the ratification of Ernst & Young LLP as the independent auditor.
Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions
Akebia Therapeutics (AKBA) is projected to grow earnings by 51.9% and revenue by 6.2% annually, with EPS expected to grow by 51.6% per year. However, recent analyst commentary highlights reassessments after lower-than-expected Q4 Vafseo revenue, attributed to a new US Renal Care dosing protocol and channel inventory effects, leading to trimmed price targets. The company is actively advancing its pipeline with clinical trials for kidney diseases, aiming for future profitability and market expansion.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages
Akebia Therapeutics (NASDAQ:AKBA) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $5.25. The company's shares recently rose 6.1% to $1.56, with a market cap of $417.9 million, after reporting a quarterly loss of $0.05 per share (missing estimates) but exceeding revenue expectations with $57.6 million. Insider and institutional activity shows CEO John Butler acquiring shares, while significant institutional investors like Goldman Sachs and JPMorgan increased their holdings.
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, an internally developed HIF-PH inhibitor. The drug is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. This development is part of Akebia's broader pipeline of kidney disease programs, which also includes praliciguat for focal segmental glomerulosclerosis and AKB-097 for rare kidney diseases.
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
This article highlights three promising penny stocks in the U.S. market: Akebia Therapeutics (AKBA), SNDL (SNDL), and Treace Medical Concepts (TMCI). While penny stocks carry risks, these companies are noted for their potential based on recent financial performance, strategic developments, and market positions. The U.S. market itself shows robust growth, providing a favorable context for such investment opportunities.
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor designed to treat cardiac surgery-associated acute kidney injury (AKI). The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AKB-9090 in healthy adults, with top-line data expected in early 2027. This drug is part of Akebia's broader pipeline of kidney disease programs, which also includes praliciguat and AKB-097.
Akebia starts human testing of drug for kidney injury after heart surgery
Akebia Therapeutics has dosed the first participants in a Phase 1 clinical trial of AKB-9090, an IV HIF-PH inhibitor for cardiac surgery-associated acute kidney injury (AKI). The study aims to enroll up to 70 participants to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with topline data expected in early 2027. This advancement further expands Akebia's kidney-focused pipeline, which also includes praliciguat and AKB-097.
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics announced that the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. The company is also developing praliciguat for focal segmental glomerulosclerosis and AKB-097 for rare kidney diseases.
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics has dosed the first participants in a Phase 1 clinical trial for AKB-9090, an internally developed HIF-PH inhibitor. This drug is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. The company is also progressing other pipeline candidates for kidney diseases, including praliciguat and AKB-097.
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. This trial will evaluate AKB-9090 as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. The company is also developing other kidney disease treatments, including praliciguat and AKB-097.
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Akebia Therapeutics (NASDAQ:AKBA) from a "strong sell" to a "hold" rating. The company's analyst coverage currently includes a consensus "Moderate Buy" rating with an average target price of $5.25. Akebia Therapeutics recently missed EPS estimates but exceeded revenue expectations, and the article details recent insider trading activity.
